Skip to main content
. 2020 Sep 17;20:371. doi: 10.1186/s12886-020-01637-0

Table 1.

Persistent diabetic macular edema through 3 and 6 months

Patients with persistent DME Month 3 (week 12)
(n/N, %)
Month 6 (week 24)
(n/N; %)
Aflibercept (Eylea®) 95/187 (50.80%) 60/190 (31.58%)
Ranibizumab (Lucentis®) 91/171 (53.22%) 73/176 (41.48%)
Bevacizumab (Avastin®) 129/177 (72.88%) 118/180 (65.56%)

At 24 weeks, p < 0.001 for aflibercept vs bevacizumab, p = 0.05 for aflibercept vs ranibizumab and p < 0.001 for ranibizumab vs bevacizumab

Source: Bressler NM, et al. JAMA Ophthalmol. 2018;136(3):257–69 [6].